Clinical Profile of an Atypical Antipsychotic: Risperidone
John A. Davis and Nancy Chen

Schematic for the haloperidol-responsive, haloperidol-nonresponsive, serotonin-sensitive, and dopamine-sensitive scales

Risperidone dose response

Analysis of acute schizophrenia symptoms

Meta-analysis of the effect of acute versus chronic status on differential outcome to risperidone and haloperidol

Meta-analysis of the PANSS total and five factor scores of risperidone versus haloperidol

Figure 1. Improvement in the PANSS total score and the five factor scores:

• (1a) from baseline to week 8 for placebo, haloperidol, and risperidone 6-16 mg/day (LOCF analysis)
• (1b) Mean percent changes from baseline to week 8 (LOCF analysis) for the individual dose groups
• (1c) Endpoint improvement of the five factors for the individual dose groups

Figure 2. Percent Improvement at Week 2 and after Week 2 on:

• (2a) the PANSS Total and Five Factor Scores
• (2b) on the haloperidol-responsive, haloperidol-nonresponsive, serotonin-sensitive, and dopamine-sensitive scales

Figure 3. Cumulative response rate of at least 20% improvement on two different ratings

Table 1. Differences between risperidone 6 mg/day and risperidone 10-16 mg on the 30 PANSS items and total score

Table 2. Interaction effects between treatment and antiparkinsonian agent or total parkinsonism

Table 3. Association between total parkinsonism (EPS) and PANSS total score, the five factors, haloperidol-responsive, haloperidol-nonresponsive, dopamine-sensitive, and serotonin-sensitive scales for haloperidol